A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
Pfizer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Roswell Park Cancer Institute
Vejle Hospital
RemeGen Co., Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
UNICANCER
City of Hope Medical Center
First Affiliated Hospital of Guangxi Medical University
Ruijin Hospital
Institut Bergonié
IFOM ETS - The AIRC Institute of Molecular Oncology
First Affiliated Hospital of Guangxi Medical University
Memorial Sloan Kettering Cancer Center
Pfizer
City of Hope Medical Center
Baylor College of Medicine
NRG Oncology